In particular, anti‐immune checkpoint therapies such as PD1/PD‐L1 inhibitors, provide clinical benefits to ≈ 30% of patients with advanced disease.[47, 48] Thus, identifying novel targets and developing combinatory treatment regimens is imperative to improve treatment outcomes for the majority of patients with recurrent BC. The gene discussed is CD274; the disease is breast cancer.